Form 4: Vertex Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director Terrence C. Kearney acquired 3,142 stock options in Vertex Pharmaceuticals on May 1, 2024, at an exercise price of $399.71.
Summary
- On May 1, 2024, Terrence C. Kearney, a director of Vertex Pharmaceuticals, acquired 3,142 stock options.
- The exercise price for these options is $399.71.
- The options are fully vested and expire on April 30, 2034.
- Following the transaction, Kearney directly owns 3,142 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction filing, and the acquisition of stock options by a director is generally viewed as a slightly positive sign.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard regulatory filing related to insider transactions. It's common for directors and officers of publicly traded companies to receive and exercise stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of stock option acquisition |
| 04/30/2034 | Expiration date of the stock options |
| 05/03/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.